The U.S. Food and Drug Administration has scheduled a September 23, 2026 meeting of its Molecular and Clinical Genetics Panel to review Grail’s premarket approval application for Galleri, a multi-cancer early detection blood test that uses machine learning to spot DNA fragments shed by tumors before a patient has any symptoms. If cleared, Galleri would become the first multi-cancer early detection test to win full FDA approval, a milestone that has been years in the making since the agency granted it Breakthrough Device status back in 2018.
Galleri works by sequencing cell-free DNA circulating in a patient’s blood and using an AI classifier trained on methylation patterns, chemical markers on DNA that behave differently in cancerous versus healthy cells, to flag a signal from more than 50 different cancer types from a single draw. When the algorithm detects a signal, a second model estimates where in the body the cancer likely originated, information doctors say is critical for deciding which follow-up scans or biopsies to order next.
A Complicated Scientific Backdrop
The advisory panel review does not arrive on the heels of unambiguous success. A three-year, NHS-run trial of more than 140,000 asymptomatic adults in the UK reported earlier this year that Galleri failed to produce a statistically significant reduction in late-stage cancer diagnoses compared with standard care, the primary endpoint the trial was designed to prove. Grail has pointed to a favorable trend toward fewer stage III and IV diagnoses across a defined group of twelve cancer types as a partial silver lining, but critics say a trend that misses statistical significance is not the same as proof the test saves lives.
What Grail Is Bringing to the FDA Instead
Rather than resting its case on the UK data alone, Grail’s premarket application leans heavily on its US-based PATHFINDER 2 study, which followed 25,490 consented participants for at least one year, along with early results from the prevalent screening round of the NHS-Galleri trial covering more than 70,000 additional participants. Company executives argue that performance metrics from these larger, more diverse cohorts, including how often the test correctly predicts the tissue of origin when it flags a signal, better reflect how the tool would perform in real-world US screening populations than the UK’s single primary endpoint.
The Commercial Reality Driving Urgency
Galleri is already sold in the US as a laboratory-developed test that consumers and some employers can order without FDA approval, and the numbers suggest demand is real: Grail reported more than 61,000 tests sold in the second quarter of 2026 alone, a 35% jump in volume from the same period a year earlier. But that offering exists in a regulatory gray zone that limits insurance reimbursement and keeps the test out of most standard-of-care screening guidelines. Full FDA approval would open the door to broader physician adoption and, eventually, payer coverage, transforming Galleri from an out-of-pocket option into a mainstream screening tool.
Wall Street Is Watching the Odds Closely
Analysts covering Grail are treating the advisory panel vote as the real test, since the FDA has historically followed its advisory committees’ recommendations in the vast majority of cases. TD Cowen analyst Dan Brennan has put the odds of eventual approval at around 75%, based partly on the historical pattern that the FDA sides with its advisory panels roughly 80% of the time. Grail’s own CEO, Josh Ofman, has told investors he expects a final approval decision in the first part of 2027, assuming the September panel meeting goes well.
Why the Debate Extends Beyond One Company
Galleri’s outcome carries weight for the entire multi-cancer early detection category, a field that includes rival tests in earlier stages of development from companies racing to prove that AI-driven blood screening can catch cancers current guidelines miss entirely, particularly cancers like pancreatic and ovarian that lack any recommended screening test today. A negative panel vote could chill investment and regulatory optimism across the category; a positive one could accelerate a wave of similar submissions. Oncologists on both sides of the debate agree on one point: whatever the panel decides, the question of whether earlier detection through blood-based AI screening actually extends lives, versus simply detecting cancers earlier without changing outcomes, will take years of follow-up data to answer definitively.
What to Watch in September
The advisory committee’s public meeting will include presentations from Grail, FDA scientific staff, and independent experts, followed by a vote on whether the agency has enough evidence to approve Galleri for its intended use. Patient advocacy groups and screening guideline bodies are expected to weigh in as well, given how directly the outcome could reshape cancer screening recommendations. Regardless of the vote, the broader rollout of AI-interpreted liquid biopsy screening is unlikely to slow, but a favorable FDA decision would mark the moment multi-cancer blood testing shifts from a promising but unproven concept to a cleared medical device available to a much wider population.
